- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06523777
PRISM: Patient Experiences With PET Imaging in Prostate Cancer (PRISM)
Optimizing Prostate Cancer Care: Integrating Risks, Benefits and Patient Experiences in the New Era of Molecular Imaging
Study Overview
Status
Conditions
Detailed Description
The primary objective is to measure health related quality of life among patients with prostate cancer who are undergoing prostate specific membrane positron emission tomography (PSMA-PET) imaging. This will be assessed in four domains: cancer related anxiety, decisional conflict, health related quality of life (physical functioning) and health preferences.
The secondary objective is to conduct longitudinal in-depth qualitative interviews to better explore patient experiences and perspectives on PET imaging.
Study Design Investigators will conduct a longitudinal explanatory sequential mixed methods study consisting of two phases. In the first phase, serial quantitative psychological (anxiety, uncertainty) and HRQoL survey data from patients undergoing PET imaging in routine clinical care will be collected. In the second phase, a subset of patients from phase 1 who have completed initial surveys will be recruited and conduct longitudinal in-depth qualitative interviews to better explore patient experiences and perspectives on PET imaging.
Patient clinical and sociodemographic data will be collected through automated extraction from the medical record (EPIC) into the REDcap database through collaboration with JDAT. For fields that are not populated via automated methods we will manually enter information via abstraction of the patient's medical record (EPIC).
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Connecticut
-
Bridgeport, Connecticut, United States, 06611
- Yale New Haven Health Bridgeport Hospital - Park Ave Medical Center
-
Derby, Connecticut, United States, 06418
- Griffin Hospital
-
Greenwich, Connecticut, United States, 06830
- Yale New Haven Health Greenwich Hospital
-
New Haven, Connecticut, United States, 06520
- Radiology and Biomedical Imaging - New Haven - Smilow Cancer Hospital (North Pavilion):
-
New Haven, Connecticut, United States, 06520
- Saint Raphael's Radiology and Biomedical Imaging, Basement Location.
-
New London, Connecticut, United States, 06320
- Yale New Haven Health Lawrence & Memorial Hospital
-
-
Rhode Island
-
Westerly, Rhode Island, United States, 02891
- Yale New Haven Health Westerly Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Documented diagnosis of prostate cancer
- Scheduled for their FIRST PSMA PET scan for prostate cancer
- English-speaking
- Willing and able to complete 4 surveys electronically or on paper at 3 timepoints (within 1 month after PET scan, 3-6 months, 12 months)
- Able to use mobile device (smartphone or tablet) or computer with web access to complete study surveys or able to complete paper surveys
Exclusion Criteria:
- Lack of access to a mobile device (smartphone or tablet) or computer with web access or unable to receive surveys by mail.
- Unable to give consent and be enrolled
- PET scan is being conducted within a clinical trial
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Memorial Anxiety Scale for Prostate Cancer (MAX-PC)
Time Frame: baseline, 3-6 months, and 12 months
|
An 18-item instrument assessing frequency of anxiety in response to prostate cancer with 4 Likert responses ranging from 0 (not at all) to 3 (often); total score range 0 to 54).
Higher scores indicate more anxiety.
|
baseline, 3-6 months, and 12 months
|
|
Change in Decisional Conflict Scale (DCS)
Time Frame: baseline, 3-6 months, and 12 months
|
A 16-item instrument using a 5-point Likert scale, ranging from 0 (strongly agree)-4 (strongly disagree), that has been widely applied to understand decision-making in prostate cancer.
Higher scores indicate greater degrees of decisional conflict.
DCS subscales include patient perceptions of uncertainty in choosing among treatment options, the contribution of modifiable factors (e.g., feeling uninformed), and effectiveness of decision-making (e.g., satisfaction with the choice).
Total and subscale scores range from 0 to 100.
|
baseline, 3-6 months, and 12 months
|
|
Change in Expanded Prostate Cancer Index Composite Short Form (EPIC-26)
Time Frame: baseline, 3-6 months, and 12 months
|
A 26 item prostate cancer specific health-related quality of life (HRQOL) questionnaire assessing urinary incontinence, urinary irritative/obstructive, bowel, sexual and hormonal domains.
Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better HRQOL.
|
baseline, 3-6 months, and 12 months
|
|
Change in EuroQol-5 Dimension (EQ-5D)
Time Frame: baseline, 3-6 months, and 12 months
|
The instrument assesses five dimensions including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
EQ-5D values can be converted to calculate health utilities that will be used for estimation of quality adjusted life years in decision analytic modeling.
EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each dimension has 5 levels: 1= no problems, 2= slight problems, 3=moderate problems, 4= severe problems, and 5= extreme problems.
Higher scores indicated greater levels of problems across each of the five dimensions.
A utility score was obtained by using a weighted combination of the levels of the five dimension-scales.
|
baseline, 3-6 months, and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Qualitative interviews on patient experiences and perspectives on PET imaging.
Time Frame: baseline, 3-6 months, and 12 months
|
Longitudinal in-depth qualitative interviews to better explore patient experiences and perspectives on PET imaging to assess emergent themes.
A subset of patients will be invited to participate in parallel in depth focused interviews occurring at three time points matching those of the surveys.
Sample size will be dynamic and assessed based on emergent themes that become apparent during coding and analysis of interviews.
|
baseline, 3-6 months, and 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael Leapman, MD, Yale University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2000037284
- 1R01CA281959-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.